Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Study sponsor: Black Diamond Therapeutics, Inc. · BDTX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-03Estimated
Enrollment · participants220Estimated
Source updated2026-11-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.